After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Novo Nordisk's (NVO-0.43%) semaglutide is everywhere in the news, and for good reason. Thanks to its ability to help people lose weight and control their diabetes symptoms, ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Novo Nordisk is requesting a stop to all alleged false advertisement, trademark infringement, and compounded semaglutide products from these businesses. Editor’s picks The 100 Best TV Episodes ...

Novo Nordisk's (NYSE: NVO) semaglutide is everywhere in the news, and for good reason. Thanks to its ability to help people lose weight and control their diabetes symptoms, its moneymaking ...